Information  X 
Enter a valid email address

Accrol Group Hldgs (ACRL)

  Print      Mail a friend

Tuesday 12 June, 2018

Accrol Group Hldgs

Directors' Dealings

RNS Number : 1637R
Accrol Group Holdings PLC
12 June 2018
 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

12 June 2018

                                                                              Accrol Group Holdings plc

(AIM: ACRL) 

 

Directors' Dealings

 

Accrol Group Holdings plc (the "Company" or "Accrol"), the AIM-listed leading independent tissue converter, is pleased to announce that, as part of the recent open offer announced on 7 June 2018, certain directors of Accrol have purchased in aggregate 81,807 ordinary shares of £0.001 each ("Ordinary Shares") at a price of 15p per Ordinary Share as set out below.

 



 

 

Number of Shares

 

 

Value of Shares

 

 

Resulting Shareholding

Percentage of Enlarged Share Capital

Name

Title





Daniel Wright

Executive Chairman

71,807

£10,771.05

1,820,308

0.93%

Gareth Jenkins

Chief Executive Officer

10,000

£1,500.00

610,000

0.31%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

i)             Dan Wright

ii)            Gareth Jenkins

 

2

Reason for the notification

a)

Position/status

i)            Executive Chairman

ii)           Chief Executive Officer

 

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Accrol Group Holdings plc

b)

LEI

213800MC56M5G69RJ226

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.001

 

ISIN: GB00BZ6VT592

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

15p

 

Volume(s)

i) 71,807

ii) 10,000

 

d)

Aggregated information

- Aggregated volume

- Price


N/A - single transaction

e)

Date of the transaction

8 June 2017

f)

Place of the transaction

London Stock Exchange, AIM

 

Enquiries:

 

For further information, please contact:

 

 

 

Accrol Group Holdings plc

 

Gareth Jenkins, Chief Executive Officer

+44 (0) 1254 278 844

Steve Townsley, Chief Finance Officer

+44 (0) 1254 278 844

 

 

Zeus Capital Limited (Nominated Adviser & Broker) 

 

Dan Bate / Andrew Jones

+44 (0) 161 831 1512

Dominic King / John Goold

+44 (0) 203 829 5000

 

 

Belvedere Communications Limited

 

Cat Valentine ([email protected])

+44 (0) 7715 769 078

Llew Angus ([email protected])

+44 (0) 7407 023 147

 

Notes to Editors

 

Accrol Group Holdings plc, based in Lancashire, is a leading tissue converter and supplier of toilet rolls, kitchen rolls and facial tissues, as well as other tissue products, to major discounters and grocery retailers throughout the UK. 

 

Accrol operates from three sites:

 

·      A manufacturing, storage and distribution facility in Blackburn;

·      A facial tissue plant, also in Blackburn; and

·      A manufacturing, storage and distribution facility in Leyland.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHDMGMVDZKGRZM

a d v e r t i s e m e n t